We recommend deferring the HSCTs until the risks associated with the COVID-19 pandemic have passed: non-urgent indications (i.e. Multiple Myeloma in first complete remission - As some novel agents like Ibrutinib or Daratumumab aren’t easily available for multiple myeloma patients, we can only defer auto- HSCT for patients in their first complete remission -, low-grade lymphoproliferative diseases, and consolidative transplants for solid tumors such as germ cell tumors) and non-malignant indications.